On Thursday, Bristol Myers Squibb & Co BMY posted fourth-quarter revenues of $12.34 billion, beating the consensus of $11.57 billion.
Gross sales elevated 8% year-over-year, or 9% when adjusted for overseas alternate impacts, primarily pushed by the Progress Portfolio and better demand for Eliquis, partially offset by the impression of generics on Sprycel, Revlimid, Abraxane and Pomalyst.
Progress Portfolio worldwide revenues elevated to $6.36 billion, representing development of 21% on a reported foundation or 23% when adjusted for overseas alternate impacts.
Additionally Learn: Huge Biopharma Trails Behind The Market: JP Morgan’s 2025 Outlook on Eli Lilly, Merck, and Extra
Opdivo gross sales elevated 4% to $2.48 billion. The arthritis drug Orencia generated gross sales of $1 billion, up 2%. Gross sales of one other most cancers drug, Yervoy, elevated 19% to $675 million.
Anemia drug Reblozyl generated $547 million within the quarter gross sales, up 71% from a 12 months in the past. Revenues for the Legacy Portfolio have been $5.98 billion, down 4%.
The corporate reported an adjusted EPS of $1.67, down from $1.70 a 12 months in the past, beating the consensus of $1.46.
Bristol Myers Squibb expanded its current strategic productiveness initiative to incorporate roughly $2 billion in further annualized price financial savings by the tip of 2027.
Within the third quarter of 2024, the corporate outlined cost-saving initiatives and anticipated inner price financial savings of round $1.5 billion in 2025.
Steerage: Bristol Myers Squibb forecasts 2025 adj EPS of $6.55-$6.85 in comparison with the consensus of $6.92. The corporate forecasts 2025 gross sales of $45.5 billion versus the consensus of $46.27 billion.
The U.S. pharma large estimates income forecast displays, as beforehand anticipated, the near-term impression of generics throughout Revlimid, Pomalyst, Sprycel and Abraxane, which is predicted to lead to a income decline of roughly 18-20% of the Legacy Portfolio.
That is anticipated to be partially offset by the continued energy of the Progress Portfolio. This steering additionally displays an approximate $500 million anticipated detrimental impression to income because of overseas alternate.
Worth Motion: On the final test on Thursday, BMY inventory was down 4.04% to $57.30.
Learn Subsequent:
Picture by way of Bristol-Myers Squibb
Market Information and Information dropped at you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
